{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:59:37Z","timestamp":1769054377725,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013774","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000}}],"reference-count":200,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013774.pub2","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T23:09:15Z","timestamp":1697065755000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy for advanced or metastatic urothelial carcinoma"],"prefix":"10.1002","volume":"2023","author":[{"given":"Philipp","family":"Maisch","sequence":"additional","affiliation":[{"name":"Department of Urology; Rechts der Isar Medical Center, Technical University of Munich; Munich Germany"},{"name":"Department of Urology and Pediatric Urology; University Hospital Ulm, University of Ulm; Ulm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eu Chang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Urology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwangmin","family":"Kim","sequence":"additional","affiliation":[{"name":"Graduate school; Yonsei University Wonju College of Medicine; Wonju Korea, South"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram M","family":"Narayan","sequence":"additional","affiliation":[{"name":"Department of Urology; Emory University; Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Bakker","sequence":"additional","affiliation":[{"name":"Health Sciences Libraries; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kunath","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology; Klinikum Bayreuth; Bayreuth Germany"},{"name":"UroEvidence@Deutsche Gesellschaft f\u00fcr Urologie; Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"},{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/JCO.2017.35.15_suppl.4501","article-title":"Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC)","volume":"35","author":"Bajorin","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"15 Suppl","DOI":"10.1200\/JCO.2021.39.15_suppl.4532","article-title":"Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial","volume":"29","author":"Bellmunt","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013774.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.2018.36.6_suppl.410","article-title":"Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)","volume":"36","author":"Bellmunt","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013774.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"v623","DOI":"10.1093\/annonc\/mdx440.031","article-title":"Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): mature results from the phase 3 KEYNOTE-045 trial","volume":"28","author":"De Wit","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1200\/JCO.2017.35.15_suppl.4530","article-title":"Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045","volume":"35","author":"De Wit","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2018.36.15_suppl.4521","article-title":"Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial","volume":"36","author":"Fradet","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013774.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013774.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/ajco.13541","article-title":"Three-year follow-up from the Phase 3 KEYNOTE-045 trial: pembrolizumab versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer","volume":"16","author":"Gurney","year":"2020","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0959-8049(17)30092-8","article-title":"Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study","volume":"72","author":"Necchi","year":"2017","journal-title":"European Journal of Cancer"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013774.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"v298","DOI":"10.1093\/annonc\/mdx371.006","article-title":"Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator's choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)","volume":"28","author":"Petrylak","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0012|cit12","first-page":"56","article-title":"Health-related quality of life (HRQOL) of pembrolizumab vs chemotherapy for previously treated advanced urothelial cancer (UC) in keynote-045","volume":"13","author":"Quinn","year":"2017","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0013|cit13","first-page":"35","article-title":"Keynote-045: open-label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer","volume":"13","author":"Quinn","year":"2017","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2017.35.6_suppl.282","article-title":"Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer","volume":"35","author":"Vaughn","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD013774.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2018.36.15_suppl.4524","article-title":"Updated efficacy and safety of KEYNOTE-052: a single-arm phase 2 study investigating firstline pembrolizumab (pembro) in cisplatin ineligible advanced urothelial cancer (UC)","volume":"36","author":"Vuky","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1538-7445.AM2021-CT040","article-title":"Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130","volume":"81","author":"Davis","year":"2021","journal-title":"Cancer Research"},{"issue":"395","key":"10.1002\/14651858.CD013774.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"16","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2021.39.6_suppl.434","article-title":"Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study","volume":"39","author":"Galsky","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/JCO.2020.38.15_suppl.5011","article-title":"Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study","volume":"38","author":"Galsky","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013774.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"IMvigor130: efficacy and safety from a Phase 3 study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)","volume":"30","author":"Grande","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013774.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"v888","DOI":"10.1093\/annonc\/mdz394.047","article-title":"IMvigor130: efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo 1 PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)","volume":"30","author":"Grande","year":"2019","journal-title":"Annals of Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2022.40.6_suppl.439","article-title":"First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): the ARIES trial","volume":"40","author":"Iacovelli","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013774.pub2-BIB0024|cit24","first-page":"27","article-title":"Correlation of inflammatory biomarkers and patient-reported outcomes in patients with urothelial carcinoma treated with durvalumab","volume":"5","author":"Degboe","year":"2017","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1200\/JCO.2017.35.15_suppl.4525","article-title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC)","volume":"35","author":"Hahn","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"10.1002\/14651858.CD013774.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti\u2013programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0027|cit27","first-page":"0","article-title":"Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma","volume":"78","author":"O'Donnell","year":"2018","journal-title":"Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD013774.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/cncr.32532","article-title":"Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced\/metastatic urothelial carcinoma treated with durvalumab in phase 1\/2 dose-escalation study 1108","volume":"126","author":"O'Donnell","year":"2020","journal-title":"Cancer"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1200\/JCO.2018.36.15_suppl.4532","article-title":"Patient-reported outcomes (PROs) in patients with urothelial carcinoma (UC) treated with durvalumab (second-line or above) in phase 1\/2 dose-escalation study 1108","volume":"36","author":"O'Donnell","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.2017.35.6_suppl.286","article-title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma","volume":"35","author":"Powles","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013774.pub2-BIB0031|cit31","first-page":"e172411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"Journal of the American Medical Association Oncology"},{"issue":"19","key":"10.1002\/14651858.CD013774.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD013774.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2019.37.7_suppl.428","article-title":"Avelumab treatment in metastatic urothelial carcinoma: post-hoc analysis of high-risk populations in the phase Ib JAVELIN Solid Tumor Study","volume":"37","author":"Apolo","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013774.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"v300","DOI":"10.1093\/annonc\/mdx371.010","article-title":"Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: Updated analysis with >=6 months of follow-up in all patients","volume":"28","author":"Apolo","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD013774.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.2019.37.7_suppl.425","article-title":"Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: updated safety and efficacy analysis with > two years of follow-up","volume":"37","author":"Apolo","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2017.35.15_suppl.4528","article-title":"Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study","volume":"35","author":"Apolo","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD013774.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2016.34.15_suppl.4514","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: analysis of safety, clinical activity, and PD-Li expression","volume":"34","author":"Apolo","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1200\/jco.2016.34.2_suppl.367","article-title":"Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial","volume":"34","author":"Apolo","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2018.36.5_suppl.166","article-title":"Avelumab in patients with previously treated mesothelioma: updated phase 1b results from the JAVELIN Solid Tumor trial","volume":"36","author":"Hassan","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013774.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013774.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2017.35.6_suppl.330","article-title":"Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial","volume":"35","author":"Patel","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"VI267","DOI":"10.1093\/annonc\/mdw373.05","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible","volume":"27","author":"Patel","year":"2016","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013774.pub2-BIB0044|cit44","first-page":"E335","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial (vol 19, pg 51, 2018)","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncology"},{"issue":"10122","key":"10.1002\/14651858.CD013774.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/s0140-6736(17)33297-x","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2017","journal-title":"Lancet"},{"issue":"10156","key":"10.1002\/14651858.CD013774.pub2-BIB0046|cit46","first-page":"1402","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (vol 391, pg 748, 2018)","volume":"392","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"10122","key":"10.1002\/14651858.CD013774.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"v365","DOI":"10.1093\/annonc\/mdz249.017","article-title":"Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the phase III IMvigor211 study","volume":"30","author":"Van Der Heijden","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013774.pub2-BIB0049|cit49","first-page":"325","article-title":"Atezolizumab (atezo) vs chemotherapy (chemo) in platinum treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study","volume":"41","author":"Von Amsberg","year":"2018","journal-title":"Oncology Research and Treatment"},{"issue":"1","key":"10.1002\/14651858.CD013774.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024.","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the Phase 3 IMvigor211","volume":"80","author":"Heijden","year":"2021","journal-title":"European Urology"},{"issue":"12","key":"10.1002\/14651858.CD013774.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","journal-title":"2020"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013774.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/annonc\/annonc274","article-title":"A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)","volume":"31","author":"Powles","year":"2020","journal-title":"Annals of Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2021.39.6_suppl.439","article-title":"Impact of subsequent therapy on survival in KEYNOTE-361: pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC)","volume":"39","author":"Alva","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1200\/JCO.2021.39.6_suppl.435","article-title":"Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361","volume":"39c","author":"Loriot","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2021.39.6_suppl.448","article-title":"Analysis of PFS2 by subsequent therapy in KEYNOTE-361: pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC)","volume":"39","author":"Ozguroglu","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1200\/JCO.2021.39.6_suppl.450","article-title":"1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361","volume":"39","author":"Powles","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013774.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncology"},{"issue":"Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0058|cit58","first-page":"15","article-title":"Phase 3 KEYNOTE-361 trial: pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer","volume":"35","author":"Powles","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013774.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2018.36.6_suppl.414","article-title":"Nivolumab monotherapy in metastatic urothelial carcinoma: longer-term efficacy and safety results from the CheckMate 032 study","volume":"36","author":"Sharma","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0061|cit61","unstructured":"A study of nivolumab in participants with metastatic or unresectable bladder cancer ClinicalTrials.gov\/show\/NCT02387996"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013774.pub2-BIB0062|cit62","first-page":"114","article-title":"Efficacy update of Nivolumab monotherapy in patients with metastatic or surgically unresectable locally advanced urothelial carcinoma who have received prior platinum-based treatment: Phase II CheckMate 275 study","volume":"40","author":"Bedke","year":"2017","journal-title":"Oncology Research and Treatment"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"VI567","DOI":"10.1093\/annonc\/mdw435.24","article-title":"Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: results from the phase II CheckMate 275 study","volume":"27","author":"Galsky","year":"2016","journal-title":"Annals of Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0064|cit64","first-page":"vi552","article-title":"Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: results from the phase II CheckMate 275 study","volume":"27","author":"Galsky","year":"2016","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1200\/JCO.2017.35.15_suppl.4526","article-title":"Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275","volume":"35","author":"Necchi","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013774.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10147-019-01450-w","article-title":"Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses","volume":"24","author":"Ohyama","year":"2019","journal-title":"International Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/s1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013774.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/JCO.2016.34.15_suppl.4501","article-title":"Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): results from the phase I\/II CheckMate 032 study","volume":"34","author":"Sharma","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0069|cit69","first-page":"0","article-title":"Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: efficacy and safety update and association between biomarkers and overall survival in","volume":"78","author":"Sharma","year":"2018","journal-title":"Cancer Research"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013774.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2019.37.15_suppl.4524","article-title":"Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: efficacy and safety update from CheckMate 275","volume":"37","author":"Siefker-Radtke","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013774.pub2-BIB0071|cit71","first-page":"44","article-title":"Nivolumab monotherapy in patients with advanced platinum resistant urothelial carcinoma: efficacy and safety update and association between biomarkers and overall survival in CheckMate 275","volume":"41","author":"Von Amsberg","year":"2018","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"e1579","DOI":"10.1016\/S2666-1683(20)33652-1","article-title":"Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with refractory\/metastatic urothelial carcinoma: preliminary results of an open-label phase II clinical study","volume":"19","author":"Chen","year":"2020","journal-title":"European Urology Open Science"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1200\/JCO.2020.38.6_suppl.504","article-title":"Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: preliminary results of an open-label phase II clinical study (POLARIS-03)","volume":"38","author":"Sheng","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0074|cit74","first-page":"15","article-title":"Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: preliminary results of an open-label phase II clinical study","volume":"37","author":"Sheng","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013774.pub2-BIB0075|cit75","first-page":"x26","article-title":"Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): results from an ongoing phase I\/II study","volume":"29","author":"Sandhu","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013774.pub2-BIB0076|cit76","first-page":"v356","article-title":"First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L11 locally advanced or metastatic urothelial carcinoma (UC) in Asian patients","volume":"30","author":"Ye","year":"2019","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013774.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Science"},{"issue":"11","key":"10.1002\/14651858.CD013774.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/s1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncology"},{"issue":"10064","key":"10.1002\/14651858.CD013774.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"VI567","DOI":"10.1093\/annonc\/mdw435.25","article-title":"Pembrolizumab (pembro) as first-line therapy for advanced\/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study","volume":"27","author":"Balar","year":"2016","journal-title":"Annals of Oncology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.2017.35.6_suppl.284","article-title":"Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from the total KEYNOTE-052 study population","volume":"35","author":"Balar","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013774.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1200\/JCO.2019.37.15_suppl.4546","article-title":"KEYNOTE-052: phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC) \u2013 updated response and survival results","volume":"37","author":"O'Donnell","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2017.35.15_suppl.4502","article-title":"Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)","volume":"35","author":"O'Donnell","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/S1569-9056(17)30236-1","article-title":"Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: results from subgroup analyses of KEYNOTE-052","volume":"16","author":"Powles","year":"2017","journal-title":"European Urology, Supplements"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD013774.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"VIII320","DOI":"10.1093\/annonc\/mdy283.110","article-title":"Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): post hoc analysis of KEYNOTE-045","volume":"29","author":"Bellmunt","year":"2018","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013774.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/S1569-9056(18)30938-2","article-title":"Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): results from Keynote-052","volume":"17","author":"Castellano","year":"2018","journal-title":"European Urology, Supplements"},{"issue":"Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0087|cit87","first-page":"13","article-title":"Long-term exposure (LTE) to tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study","volume":"73","author":"Desai","year":"2019","journal-title":"Cancer Research"},{"issue":"16","key":"10.1002\/14651858.CD013774.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase ii study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013774.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1200\/JCO.2019.37.15_suppl.4504f","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182","volume":"37","author":"Galsky","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0090|cit90","article-title":"A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE)","volume":"39","author":"Galsky","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013774.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1200\/JCO.2022.40.6_suppl.432","article-title":"First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): a phase 3, randomized, double-blind study","volume":"40","author":"Loriot","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD013774.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0093|cit93","first-page":"15","article-title":"Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): safety analysis from an expanded access study","volume":"35","author":"Bellmunt","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0094|cit94","first-page":"15","article-title":"Atezolizumab (atezo) in special populations: analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)","volume":"36","author":"Hoffman-Censits","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013774.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.eururo.2018.02.010","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: clinical experience from an expanded access study in the United States","volume":"73","author":"Pal","year":"2018","journal-title":"European Urology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD013774.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1200\/JCO.2019.37.7_suppl.429","article-title":"Avelumab treatment in metastatic urothelial carcinoma: association between early response and durable outcomes in the phase Ib JAVELIN Solid Tumor Study","volume":"36","author":"Patel","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2017.11.023","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: outcomes by prior number of regimens","volume":"73","author":"Perez-Gracia","year":"2018","journal-title":"European Urology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0098|cit98","first-page":"e861","article-title":"A phase 1b study of pembrolizumab (pembro; mk-3475) for advanced urothelial cancer","volume":"33","author":"Gupta","year":"2015","journal-title":"Journal of Urology"},{"issue":"7 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/jco.2015.33.7_suppl.296","article-title":"Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: results of a phase IB study","volume":"33","author":"O'Donnell","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013774.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncology"},{"issue":"7528","key":"10.1002\/14651858.CD013774.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"6","key":"10.1002\/14651858.CD013774.pub2-BIB0102|cit102","first-page":"266","article-title":"A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)","volume":"27","author":"Powles","year":"2016","journal-title":"Annals of Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"TPS4586","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4586","article-title":"Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of firstline platinum-containing chemotherapy: KEYNOTE-698\/ECHO-303","volume":"36","author":"Powles","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD013774.pub2-BIB0104|cit104","first-page":"0","article-title":"Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): long-term efficacy from phase 2 study IMvigor210","volume":"36","author":"Balar","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"Suppl 7","DOI":"10.1200\/JCO.2019.37.7_suppl.394","article-title":"Long-term outcomes in elderly patients (pts) from IMvigor210: atezolizumab (atezo) in metastatic urothelial cancer (mUC)","volume":"37","author":"Balar","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"Suppl 18","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA4500","article-title":"Atezolizumab (atezo) as first-line (1L) therapy in cisplatin in eligible locally advanced\/metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1","volume":"34","author":"Balar","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"10064","key":"10.1002\/14651858.CD013774.pub2-BIB0107|cit107","first-page":"67","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","journal-title":"2017"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"Suppl 6","DOI":"10.1093\/annonc\/mdw373.10","article-title":"IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced\/ metastatic urothelial carcinoma (mUC)","volume":"27","author":"Bellmunt","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"Suppl 15","DOI":"10.1200\/JCO.2016.34.15_suppl.4515","article-title":"Updated efficacy and > 1-y follow up from IMvigor210: atezolizumab (atezo) in platinum (plat) treated locally advanced\/metastatic urothelial carcinoma (mUC)","volume":"34","author":"Dreicer","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0110|cit110","first-page":"e654","article-title":"Primary analysis of imvigor 210: atezolizumab in platinum-treated advanced urothelial carcinoma","volume":"195","author":"Dreicer","year":"2016","journal-title":"Journal of Urology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0111|cit111","first-page":"2","article-title":"IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)","volume":"34","author":"Hoffman-Censits","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0112|cit112","first-page":"e1039","article-title":"Clinical characteristics associated with early progression or long-term response from the phase ii IMvigor210 study: atezolizumab in locally advanced or metastatic urothelial carcinoma","volume":"199","author":"Joseph","year":"2018","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"Suppl 6","DOI":"10.1093\/annonc\/mdw373.11","article-title":"Atezolizumab (atezo) in platinum (plat)-treated locally advanced\/metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the Ph II IMvigor210 study","volume":"27","author":"Loriot","year":"2016","journal-title":"Annals of Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013774.pub2-BIB0114|cit114","first-page":"v289","article-title":"Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): post-progression outcomes from the phase 2 IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Annals of Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013774.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"S720","DOI":"10.1016\/S0959-8049(16)31942-6","article-title":"Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): results from a pivotal multicenter phase II study (IMvigor 210)","volume":"51","author":"Rosenberg","year":"2015","journal-title":"European Journal of Cancer"},{"issue":"10031","key":"10.1002\/14651858.CD013774.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0117|cit117","article-title":"Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): update from the IMvigor 210 phase II clinical trial","volume":"15","author":"Van Der Heijden","year":"2016","journal-title":"European Urology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD013774.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"VIII725","DOI":"10.1093\/annonc\/mdy424.038","article-title":"Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg\/kg 1 ipilimumab 3 mg\/kg expansion from Check Mate 032","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Annals of Oncology"},{"issue":"19","key":"10.1002\/14651858.CD013774.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg expansion cohort results","volume":"37","author":"Sharma","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"P174","DOI":"10.1186\/2051-1426-3-S2-P174","article-title":"A phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent","volume":"3","author":"Sharma","year":"2015","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"TPS538","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS538","article-title":"A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): urothelial and non-urothelial urinary tract carcinoma module A","volume":"36","author":"Sonpavde","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 237","key":"10.1002\/14651858.CD013774.pub2-BIB0122|cit122","first-page":"12S","article-title":"Primary results from the SAUL study: atezolizumab for locally advanced or metastatic urothelial carcinoma (UC) or non-UC","volume":"149","author":"Cathomas","year":"2019","journal-title":"Swiss Medical Weekly"},{"issue":"1","key":"10.1002\/14651858.CD013774.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","article-title":"Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract","volume":"76","author":"Sternberg","year":"2019","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"Suppl 15","DOI":"10.1200\/JCO.2019.37.15_suppl.4519","article-title":"Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract","volume":"37","author":"Sternberg","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2020.38.6_suppl.488","article-title":"Atezolizumab (atezo) therapy for upper tract (UT) urothelial carcinoma (UC): subgroup analysis of the single-arm international SAUL study in pretreated locally advanced\/metastatic urinary tract carcinoma","volume":"38","author":"Sternberg","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013774.pub2-BIB0126|cit126","first-page":"73","article-title":"Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (ATEZO) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract","volume":"43","author":"Zengerling","year":"2020","journal-title":"Oncology Research and Treatment"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.21873\/invivo.12453","article-title":"Pembrolizumab versus combined chemotherapy with gemcitabine and paclitaxel: a comparative assessment of clinical outcomes in patients with platinum-refractory advanced urothelial cancer","volume":"35","author":"Takemura","year":"2021","journal-title":"In Vivo"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"6 Suppl","DOI":"10.1200\/JCO.2020.38.6_suppl.451","article-title":"Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experience","volume":"38","author":"Tural","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/annonc\/mdz249.019","article-title":"First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic urothelial carcinoma (UC) in Asian patients","volume":"30","author":"Ye","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013774.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"v303","DOI":"10.1093\/annonc\/mdx371","article-title":"Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)","volume":"28","author":"Zhang","year":"2017","journal-title":"Annals of Oncology"},{"issue":"20","key":"10.1002\/14651858.CD013774.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1002\/cncr.33067","article-title":"A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0132|cit132","unstructured":"An open-label, multi-centre, study to assess the safety of fixed-dose durvalumab + tremelimumab combination therapy or durvalumab monotherapy in advanced solid malignancies (STRONG) clinicaltrials.gov\/ct2\/show\/NCT03084471"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD013774.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1200\/JCO.2020.38.6_suppl.484","article-title":"An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): interim safety results for fixed-dose durvalumab (D) monotherapy (module A)","volume":"38","author":"Sonpavde","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013774.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-Of-Life Instrument for Use in International Clinical Trials in Oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of National Cancer Institute"},{"issue":"10","key":"10.1002\/14651858.CD013774.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"10064","key":"10.1002\/14651858.CD013774.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD013774.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/s1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013774.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ajco.12070","article-title":"Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer","volume":"10","author":"Bedard","year":"2014","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"27","key":"10.1002\/14651858.CD013774.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013774.pub2-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013774.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"2","key":"10.1002\/14651858.CD013774.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"European Urology"},{"issue":"I6890","key":"10.1002\/14651858.CD013774.pub2-BIB0143|cit143","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0144|cit144","unstructured":"Covidence Veritas Health Innovation 2017"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD013774.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0147|cit147","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0148|cit148","unstructured":"Witjes JA Bruins HM Cathomas R Comp\u00e9rat E Cowan NC Efstathiou JA EAU guidelines on muscle-invasive and metastatic bladder cancer uroweb.org\/guidelines\/compilations-of-all-guidelines\/"},{"issue":"2","key":"10.1002\/14651858.CD013774.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0150|cit150","unstructured":"EMA restricts use of Keytruda and Tecentriq in bladder cancer www.ema.europa.eu\/en\/news\/ema-restricts-use-keytruda-tecentriq-bladder-cancer"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0151|cit151","unstructured":"EndNote Thomson Reuters 2019"},{"issue":"12","key":"10.1002\/14651858.CD013774.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2147\/OTT.S186271","article-title":"A meta-analysis of the efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer","volume":"4","author":"Fan","year":"2019","journal-title":"OncoTargets and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"703.e1","DOI":"10.1016\/j.urology.2014.10.020","article-title":"Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma","volume":"85","author":"Faraj","year":"2015","journal-title":"Urology"},{"issue":"8","key":"10.1002\/14651858.CD013774.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"International Journal of Cancer"},{"issue":"17","key":"10.1002\/14651858.CD013774.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013774.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2019.05.002","article-title":"PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: a meta-analysis","volume":"76","author":"Ghate","year":"2019","journal-title":"Cancer Treatment Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013774.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study","volume":"3","author":"Global Burden of Disease Cancer Collaboration","year":"2017","journal-title":"JAMA Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013774.pub2-BIB0159|cit159","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012556.pub2","article-title":"Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)","author":"Goldkuhle","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013774.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"540.e1","DOI":"10.1016\/j.urolonc.2017.04.016","article-title":"Physical activity patterns and associations with health-related quality of life in bladder cancer survivors","volume":"35","author":"Gopalakrishna","year":"2017","journal-title":"Urologic Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0161|cit161","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2019.05.041","article-title":"Safe use of immune checkpoint inhibitors in the multidisciplinary management of urological cancer: the European Association of Urology Position in 2019","volume":"76","author":"Grimm","year":"2019","journal-title":"European Urology"},{"issue":"7651","key":"10.1002\/14651858.CD013774.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013774.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD013774.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD013774.pub2-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0167|cit167","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0168|cit168","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604.ch8"},{"issue":"19","key":"10.1002\/14651858.CD013774.pub2-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1002\/14651858.CD013774.pub2-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013774.pub2-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013774","article-title":"Immunotherapy for advanced or metastatic urothelial carcinoma","author":"Maisch","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1016\/j.ctrv.2022.102360","article-title":"Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis","volume":"102360","author":"Martini","year":"2022","journal-title":"Cancer Treatment Reviews"},{"issue":"26","key":"10.1002\/14651858.CD013774.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti\u2013programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0174|cit174","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejca.2021.03.049","article-title":"First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"151","author":"Mori","year":"2021","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD013774.pub2-BIB0176|cit176","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012838.pub2","article-title":"Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review","author":"Narayan","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0177|cit177","unstructured":"National Comprehensive Cancer Network Guidelines in Oncology - Bladder Cancer, Version 4.2021 www.nccn.org"},{"issue":"4","key":"10.1002\/14651858.CD013774.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1002\/14651858.CD013774.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with Immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"10122","key":"10.1002\/14651858.CD013774.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/s0140-6736(17)33297-x","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013774.pub2-BIB0182|cit182","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011903.pub2","article-title":"Robotic versus open radical cystectomy for bladder cancer in adults","author":"Rai","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013774.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11136-017-1745-8","article-title":"Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases","volume":"27","author":"Raman","year":"2018","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0184|cit184","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects. In Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MG, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0185|cit185","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"10031","key":"10.1002\/14651858.CD013774.pub2-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/s0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"6024","key":"10.1002\/14651858.CD013774.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0188|cit188","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Guyatt GH Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch14"},{"issue":"11","key":"10.1002\/14651858.CD013774.pub2-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/s1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013774.pub2-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0022-5347(17)48996-8","article-title":"Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium","volume":"133","author":"Sternberg","year":"1985","journal-title":"Journal of Urology"},{"issue":"12","key":"10.1002\/14651858.CD013774.pub2-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"issue":"10","key":"10.1002\/14651858.CD013774.pub2-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/jco.2001.19.10.2638","article-title":"Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924","volume":"19","author":"Sternberg","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0194|cit194","unstructured":"Sterne JA Hern\u00e1n MA McAleenan A Reeves BC Higgins JP Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions V ersion 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0195|cit195","volume-title":"Cancer Epidemiology and Prevention","author":"Thun","year":"2018"},{"issue":"17","key":"10.1002\/14651858.CD013774.pub2-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/jco.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"Maase","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD013774.pub2-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"Maase","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"7644","key":"10.1002\/14651858.CD013774.pub2-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013774.pub2-BIB0199|cit199","doi-asserted-by":"crossref","unstructured":"Ye D Liu J Zhou A Zou Q Li H Fu C First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L11 locally advanced or metastatic urothelial carcinoma (UC) in Asian patients Annals of Oncology 2019 30 Suppl 5 v356 v402","DOI":"10.1093\/annonc\/mdz249.019"},{"issue":"12","key":"10.1002\/14651858.CD013774.pub2-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1007\/s00520-012-1484-x","article-title":"An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases","volume":"20","author":"Zeng","year":"2012","journal-title":"Supportive Care in Cancer"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:03:04Z","timestamp":1756080184000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013774.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":200,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013774.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]}}}